Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Inclusion Criteria: * Histologically confirmed follicular lymphoma that has relapsed or has failed primary therapy * Progressive disease requiring further treatment * Bidimensionally measurable disease * Acceptable hematologic status * Prestudy WHO performance status of 0, 1, or 2 * Expected survival of \>/= 3 months * Patients with reproductive potential must follow accepted birth control methods during treatment and for 3 months after completion of treatment * Female patients must not be pregnant or lactating * Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, ABMT, or investigational drugs Exclusion Criteria: * Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks of first scheduled treatment (6 weeks if nitrosourea or mitomycin-C) * Prednisone or other immunosuppressive therapy within 3 weeks of first scheduled treatment * Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to first scheduled treatment * Previous exposure to IDEC-114 or any anti-CD80 antibody * ABMT within 6 months prior to first scheduled treatment * Abnormal liver function * Abnormal renal function * Presence of chronic lymphocytic leukemia (CLL) * Presence of CNS lymphoma * Presence of HIV infection or AIDS * Prior diagnosis of aggressive non-Hodgkin's lymphoma or mantle-cell lymphoma * Another primary malignancy (other than squamous cell and basal cell carcinoma of the skin, in situ carcinoma of the cervix, or treated prostate cancer with a stable PSA) for which the patient has not been disease-free for at least 3 years * Serious nonmalignant disease which would compromise protocol objectives in the opinion of the investigator and/or the sponsor * New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to first scheduled treatment * Major surgery, other than diagnostic surgery, within 4 weeks prior to first scheduled treatment * Pleural invasion and/or effusion with positive cytology for lymphoma * Peritoneal invasion and/or ascites with positive cytology for lymphoma